Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Inovio Pharmaceuticals Inc’s stock clocked out at $1.84, down -7.07% from its previous closing price of $1.98. In other words, the price has decreased by -$7.07 from its previous closing price. On the day, 0.58 million shares were traded.
Ratios:
To gain a deeper understanding of INO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.88 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on May 14, 2024, initiated with a Overweight rating and assigned the stock a target price of $20.
On January 25, 2024, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $4.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 332.13 while its Price-to-Book (P/B) ratio in mrq is 0.65.
Stock Price History:
Over the past 52 weeks, INO has reached a high of $14.75, while it has fallen to a 52-week low of $1.74. The 50-Day Moving Average of the stock is -8.43%, while the 200-Day Moving Average is calculated to be -69.55%.
Shares Statistics:
A total of 36.10M shares are outstanding, with a floating share count of 35.88M. Insiders hold about 0.61% of the company’s shares, while institutions hold 37.08% stake in the company.
